These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15139513)

  • 1. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    Pharm Res; 2004 Apr; 21(4):574-84. PubMed ID: 15139513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.
    Jadhav PR; Agersø H; Tornøe CW; Gobburu JV
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):609-34. PubMed ID: 16967346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.
    Agersø H; Koechling W; Knutsson M; Hjortkjaer R; Karlsson MO
    Eur J Pharm Sci; 2003 Nov; 20(3):335-40. PubMed ID: 14592699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Dec; 31(6):441-61. PubMed ID: 16222784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
    Broqua P; Riviere PJ; Conn PM; Rivier JE; Aubert ML; Junien JL
    J Pharmacol Exp Ther; 2002 Apr; 301(1):95-102. PubMed ID: 11907162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk.
    Sannala CKR; MacLean C; Larsen F; van Os S; Jadhav P; Shore N; Morgans AK; Okwuosa T; Gobburu J
    Clin Pharmacol Drug Dev; 2024 Aug; 13(8):915-929. PubMed ID: 38757461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
    Wong SL; Lau DT; Baughman SA; Fotheringham N; Menchaca D; Garnick MB
    J Clin Pharmacol; 2004 May; 44(5):495-502. PubMed ID: 15102870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.
    Tornøe CW; Agersø H; Senderovitz T; Nielsen HA; Madsen H; Karlsson MO; Jonsson EN
    Br J Clin Pharmacol; 2007 Jun; 63(6):648-64. PubMed ID: 17096678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
    Samant MP; Gulyas J; Hong DJ; Croston G; Rivier C; Rivier J
    J Med Chem; 2005 Jul; 48(15):4851-60. PubMed ID: 16033265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
    Lim CN; Salem AH
    Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix.
    Barkin J; Burton S; Lambert C
    Can J Urol; 2016 Feb; 23(1):8179-83. PubMed ID: 26892063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
    J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of depot formulations of GnRH agonist leuprorelin and antagonist degarelix on the seminiferous epithelium of the rat testis.
    Hori JI; Koga D; Kakizaki H; Watanabe T
    Biomed Res; 2018; 39(4):197-214. PubMed ID: 30101840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.